The short answer is no.

The long answer is that there will be a lot of variability between different cancers. DNA damage checkpoints are often mutated early in cancers, which compromises genome fidelity. This means that cancer cells will have much higher mutation rates compared to normal healthy cells. The degree and rate of mutation will vary greatly depending on which pathways have been compromised. Some cancers can be so severely compromised that the entire genome is subjected to gross chromosomal rearrangements (e.g. ALT cancers).

If you want to narrow the field, you might want to look into "passenger mutations" which are incidental mutations which happen to segregate with oncogenic driver mutations.